Aerosol and injectable formulations of nanoparticulate benzodiazepine

Abstract

Described herein are nanoparticulate formulations of benzodiazepines, such as lorazepam, which do not require the presence of polyethylene glycol and propylene glycol as stabilizers; and methods of making and using such formulations. The formulation is especially useful in aerosol and injectable dosage forms and contains nanoparticulate benzodiazepines such as lorazepam and at least one surface stabilizer. The preparation is useful in the treatment of epileptic states, in the treatment of irritable bowel syndrome, sleep induction, acute psychosis and as a pre-anesthesia drug.

Description

field of invention [0001] The present invention relates to nanoparticle benzodiazepines, preferably nanoparticle lorazepam aerosol and injection preparation. The compositions of the invention are useful in the treatment of epileptic states, sleep induction, acute psychosis, irritable bowel syndrome and for pre-anesthesia administration. The invention also includes methods of making and using such compositions. Background of the invention [0002] I. Route of administration [0003] The route of administration of a drug is critical to its pharmacological efficacy. Various routes of administration are available, and all have advantages and disadvantages. Oral administration of tablets, capsules, liquid formulations, etc. is the most convenient method of drug delivery, but many pharmaceutical compounds are not suitable for oral administration. For example, modern protein drugs that are unstable in the acidic gastric environment or are rapidly degraded by proteolytic enzyme...

AI Technical Summary

Problems solved by technology

The '684 patent also describes methods for preparing such nanoparticulate compositions, but does not describe compositions containing benzodiazepines such as lorazepam in nanoparticulate form